Search

Your search keyword '"Winters, Amanda"' showing total 267 results

Search Constraints

Start Over You searched for: Author "Winters, Amanda" Remove constraint Author: "Winters, Amanda"
267 results on '"Winters, Amanda"'

Search Results

3. Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium

8. Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium

10. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia

11. The Feedback Loop Between Aboveground Herbivores and Soil Microbes via Deposition Processes

12. Development of a Socioecological Adolescent Sexual Health Index and Atlas: A Case Study in Washington State

14. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis

16. Supplementary Table 6 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy

17. Supplementary Table 2 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy

18. Supplementary Table 8 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy

19. Supplementary Tables 3-5 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy

20. Supplementary Table 7 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy

21. Supplementary Table 1 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy

22. Supplementary Table 9 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy

23. Supplementary Figures S1-S7 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy

24. Data from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy

28. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

29. A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy

30. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia

31. Identifying patterns of neurocognitive dysfunction through direct comparison of children with leukemia, central nervous system tumors, and sickle cell disease

32. Supplementary Figures S1-S5 from Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia

33. Supplementary Tables S1-S6 from Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia

34. Data from Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia

40. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy

41. Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study

43. Identifying Patterns of Neurocognitive Dysfunction through Direct Comparison of Patients with Leukemia, CNS Tumors, and Sickle Cell Disease

47. Sex and the Seminary: Preparing Ministers for Sexual Health and Justice

49. N‐terminus DUX4‐immunohistochemistry is a reliable methodology for the diagnosis of DUX4‐fused B‐lymphoblastic leukemia/lymphoma (N‐terminus DUX4 IHC for DUX4‐fused B‐ALL)

Catalog

Books, media, physical & digital resources